Fresenius Medical Care News - Ad hoc http://www.freseniusmedicalcare.com en_EN Wed, 18 Jul 2018 11:34:04 +0200 Wed, 18 Jul 2018 11:34:04 +0200 TYPO3 EXT:news news-1411 Sun, 22 Apr 2018 15:03:43 +0200 Ad hoc announcement according to Article 17 MAR: Fresenius Medical Care adjusts its 2018 revenue growth target and confirms its net income growth target /en/media/news/details/detail/News/ad-hoc-announcement-according-to-article-17-mar-fresenius-medical-care-adjusts-its-2018-revenue-gro/ Fresenius Medical Care, the world’s largest provider of dialysis products and services, has decided to adjust its 2018 revenue growth target from around 8 percent to a range of 5 to 7 percent at constant currency[1].

The main reason for this adjustment is the Company’s recent reassessment of dosing of calcimimetic drugs in its dialysis service business in the United States. The reduction in dosing was faster than assumed and results in a lower than expected revenue contribution.

At the same time, Fresenius Medical Care reconfirms its 2018 net income growth target of 13 to 15 percent at constant currency. The Company’s 2018 targets continue to exclude the effects of the planned acquisition of NxStage Medical, Inc. and exclude the effects of the divestiture of Sound Inpatient Physicians Holdings, LLC.

Final financial results for the first quarter 2018 will be published, as scheduled, on 3 May 2018.

---

1  2017 adjusted for the effect of IFRS 15 implementation

---

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,752 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 320,960 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.com.

]]>
news-1405 Sat, 21 Apr 2018 00:00:00 +0200 Ad hoc announcement according to Article 17 MAR: Fresenius Medical Care sells Sound Inpatient Physicians Holdings for $2.15 billion /en/media/news/details/detail/News/ad-hoc-announcement-according-to-article-17-mar-fresenius-medical-care-sells-sound-inpatient-physi/ Fresenius Medical Care, the world’s largest provider of dialysis products and services, today has signed a definitive agreement to divest its controlling interest in Sound Inpatient Physicians Holdings, LLC (“Sound”) to an investment consortium led by Summit Partners, L.P. for total transaction proceeds of $2.15 billion (EUR 1.76 billion1). The divestment is expected to generate a pre-tax book gain of approximately EUR 800 million1,2.

In 2014, Fresenius Medical Care invested in becoming the majority shareholder in Sound, which thereafter acquired Cogent Healthcare, Inc. The investments by Fresenius Medical Care were targeted to learn about and broaden its experience in value-based care programs of those businesses. Following the successful application of this knowledge relevant for value-based programs and efficient patient coordination into Fresenius Medical Care, the Company is now in a position to divest the shareholding and free up the invested capital for further growth investments.

Closing of the transaction is subject to regulatory approvals and anticipated to occur late in 2018. The financial targets for 2018 and 2020 do not include the effects of this divesture.

---

1 EUR/USD 1.22
2 based on the company’s latest available valuation of the North American business segment

]]>
news-1377 Mon, 26 Feb 2018 00:00:00 +0100 Ad hoc announcement according to Article 17 MAR: Fresenius Medical Care establishes provision of EUR 200 million regarding ongoing FCPA settlement negotiations /en/media/news/details/detail/News/ad-hoc-announcement-according-to-article-17-mar-fresenius-medical-care-establishes-provision-of-eur-200-million-regarding-ongoing-fcpa-settlement-negotiations/ Fresenius Medical Care, the world’s largest provider of dialysis products and services, has decided to establish a provision in the total amount of EUR 200m in its 2017 annual financial statements with respect to its ongoing settlement negotiations with the U.S. government regarding conduct that may have violated provisions of the U.S. Foreign Corrupt Practices Act (FCPA).

This provision takes into account recent developments in the ongoing settlement negotiations with the U.S. Department of Justice and the U.S. Securities Exchange Commission. The provision represents an estimate from a range of potential outcomes. The charge encompasses government agencies’ claims for profit disgorgement, as well as accruals for fines and/or penalties, certain legal and other consultancy expenses and other related costs or asset impairments. In 2012, Fresenius Medical Care voluntarily advised the U.S. Department of Justice and the U.S. Securities Exchange Commission about its investigations into this conduct.

The settlement negotiations are continuing and have not yet achieved an agreement-in-principle; failure to reach agreement remains possible.

]]>
news-1339 Fri, 22 Dec 2017 21:30:52 +0100 Ad hoc announcement according to Article 17 MAR: Fresenius Medical Care expects material positive effects from US tax reform /en/media/news/details/detail/News/ad-hoc-announcement-according-to-article-17-mar-fresenius-medical-care-expects-material-positive-effects-from-us-tax-reform/ Fresenius Medical Care, the world’s largest provider of dialysis products and services, expects material positive effects from the tax reform legislation signed into law in the United States today. The new law goes into effect on January 1, 2018.

In particular, the new legislation triggers the re-evaluation of deferred tax liabilities. This results in a one-time book gain of around 200 million Euros, to be reflected in 2017 Earnings After Tax.

On February 27, 2018 the company will release its 2017 business results and discuss the ongoing tax effect as part of its guidance for 2018.

]]>
news-1280 Mon, 07 Aug 2017 00:00:00 +0200 Ad hoc announcement according to Article 17 MAR: Fresenius Medical Care to acquire NxStage Medical, Inc. for approximately USD 2.0 billion. /en/media/news/details/detail/News/ad-hoc-announcement-according-to-article-17-mar-fresenius-medical-care-to-acquire-nxstage-medical/ Fresenius Medical Care, the world’s largest provider of dialysis products and services, today has signed a merger agreement to acquire NxStage Medical, Inc. (NASDAQ: NXTM), a U.S.-based medical technology and services company.

Pursuant to the merger agreement, Fresenius Medical Care North America has agreed to acquire all outstanding shares of NxStage Medical, Inc. for USD 30.00 per common share in cash.

The planned acquisition has a total transaction volume of approximately EUR1 1.7 billion (USD 2.0 billion). Closing is currently expected to occur in 2018.

Completion of the merger is subject to approval of NxStage Medical, Inc. stockholders, receipt of regulatory approvals and other customary closing conditions.

 

1 Based on an exchange rate of 0.849 USD/EUR as per 5 August 2017.

***

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,690 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 315,305 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimer Regarding Forward-Looking Statements

This release contains forward-looking statements, including statements regarding Fresenius Medical Care’s planned acquisition of NxStage Medical, Inc. and the expected timing of the closing of the transaction. Actual results could differ materially from those expressed or implied in these forward-looking statements due to certain factors, including, among others: the failure or inability of either Fresenius Medical Care or NxStage Medical, Inc. to satisfy closing conditions or obtain approvals necessary to close the transaction; unexpected costs or delays associated with efforts to obtain the regulatory or other approvals necessary to close the transaction; risks associated with litigation or regulatory actions related to the transaction; changes in business, economic and competitive conditions; regulatory reforms; foreign exchange rate fluctuations; risks and uncertainties in litigation or investigative proceedings, whether or not related to the transaction; and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

]]>
news-1130 Sat, 07 Jan 2017 00:00:00 +0100 Ad hoc announcement according to Article 17 MAR: Fresenius Medical Care: Impact of potential regulation change /en/media/news/details/detail/News/ad-hoc-announcement-according-to-article-17-mar-fresenius-medical-care-impact-of-potential-regulation-change/ Centers for Medicare and Medicaid Services (CMS) promulgated a new regulation regarding premium assistance programs that help to fund health insurance premiums for patients with end stage renal disease (ESRD).  Many financially needy Americans receive grants from nonprofit charities to help them obtain health insurance.  For decades, the American Kidney Fund (AKF) has provided such premium assistance to ESRD patients. 

The new regulation, which is scheduled to become effective on January 13, 2017, threatens to put an end to premium assistance for certain ESRD patients.  The regulation, should it become effective, and the continuing efforts by insurers – through their discussions with CMS and otherwise – to reject premium assistance for ESRD patients, may result in a material adverse effect on our business. Between 700 and 2,000 FMCNA ESRD patients who currently use premium assistance in connection with individual market plans on and off the exchanges may be impacted by the regulation and/or continuing insurer efforts to reject premium assistance.

Fresenius Medical Care Holdings, Inc. (FMCNA) has joined other providers and patient advocates in filing a lawsuit challenging the rulemaking process and stop the regulation to become effective.

On January 3, 2017, FMCNA accepted service of a subpoena from the United States Attorney for the District of Massachusetts calling for the production of information related to the premium assistance program operated by the AKF.  FMCNA is cooperating with this investigation.

]]>
news-937 Wed, 17 Feb 2016 00:00:00 +0100 Ad hoc announcement according to § 15 WpHG: Fresenius Medical Care AG & Co. KGaA reaches agreement in principle to resolve the GranuFlo(R)/NaturaLyte(R) product liability litigation /en/media/news/details/detail/News/ad-hoc-announcement-according-to-15-wphg-fresenius-medical-care-ag-co-kgaa-reaches-agreement-in-principle-to-resolve-the-granuflornaturalyter-product-liability-litigation/ Fresenius Medical Care AG & Co. KGaA ("the company" or "Fresenius Medical Care"), the world's largest provider of dialysis products and services, today announced that Fresenius Medical Care North America (FMCNA) has reached an agreement in principle with a committee designated by the plaintiffs to resolve litigation in the United States involving GranuFlo(R)/NaturaLyte(R).

Under the agreement in principle, the settlement amount would be $250 million, provided that 97% of all plaintiffs agree to the settlement by July 2016 with the funding provided in August 2016. Insurers will fund the settlement amount with $220 million.

Therefore, the company expects a pre-tax charge of $60 million from the settlement and other costs to finalize this matter. This impact for the company will be reflected in its 2015 numbers to be published on February 24, 2016.

***

Information and Explaination of the Issuer to this News:

For 2015 the company expects to report revenues of approximately $16.7 billion. Excluding the charge net of tax, the 2015 net income attributable to shareholders should increase by approximately 2% over the prior year period. On that basis the company expects to be in line with its financial guidance for 2015.

The company's GranuFlo(R)/NaturaLyte(R) product at issue in the litigation remains on the market and continues to be the market leader for dialysis acid concentrates in the United States. There has been no change in the composition of the product and it remains safe and effective when used and prescribed as directed.

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which more than 2.6 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,402 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 290,250 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.

Disclaimer This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

]]>
news-829 Wed, 25 Feb 2015 15:10:00 +0100 Fresenius Medical Care Reports Full Year 2014 Results and provides Outlook for 2015 /en/media/news/details/detail/News/fresenius-medical-care-reports-full-year-2014-results-and-provides-outlook-for-2015/ Fresenius Medical Care has achieved its targets for the fiscal year 2014.

Net revenue of Fresenius Medical Care AG & Co. KGaA increased by 8% to $15,832 million as compared to the full year 2013.

Operating income (EBIT) for the full year 2014 remained nearly flat at $2,255 million.

Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA decreased by 6% to $1,045 million.

For the 18th consecutive year shareholders can expect to receive an increased annual dividend. At the ordinary annual general meeting to be held on May 19, 2015, shareholders will be asked to approve a dividend per share of €0.78, an increase of 1% (2013: €0.77).

The information provided is based on exchange rates prevailing at the beginning of 2015. Savings from the global efficiency program are included, while potential acquisitions are not. In addition the outlook reflects further operating cost investments within the Care Coordination segment for future growth in line with our 2020 strategy.

For the full year 2015, Fresenius Medical Care expects revenue to grow at
5-7%, which at constant currency is a growth rate of 10-12%. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to increase 0-5%.

For the year 2016 we expect an acceleration of growth with a revenue increase of 9–12% and net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA growing by 15–20%.

As disclosed in the company’s long-term target for 2020 the company expects revenue to grow at an average annual growth rate of approx. 10% and net income attributable to shareholders in the high single digits.



Fresenius SE & Co. KGaA holds approximately 30.3% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA
Represented by Fresenius Medical Care Management AG
Represented by its management board
Bad Homburg v.d.H., February 25, 2015

]]>
news-160 Tue, 25 Feb 2014 10:46:00 +0100 Fresenius Medical Care Reports Full Year 2013 Results and provides Outlook for 2014 /en/media/news/details/detail/News/fresenius-medical-care-reports-full-year-2013-results-and-provides-outlook-for-2014/ Fresenius Medical Care has achieved its targets for the financial year 2013.

Net revenue of Fresenius Medical Care AG & Co. KGaA for the full year 2013 was $14,610 million, up by 6% from the full year 2012.

Operating income (EBIT) for the full year 2013 increased by 2% to $2,256 million.

Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA decreased by 6% to $1,110 million. Excluding an investment gain in the amount of $140 million in 2012, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA increased by 6%.

For the 17th consecutive year shareholders can expect to receive an increased annual dividend. At the ordinary Annual General Meeting to be held on May 15, 2014, shareholders will be asked to approve a dividend per ordinary share of €0.77, an increase of 3% (2012: €0.75).

For the full year 2014, Fresenius Medical Care expects revenue to grow to approximately $15.2 billion. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.0 billion and $1.05 billion in 2014. The company initiated a global efficiency program designed to enhance the company’s performance over a multi-year period. Potential cost savings before income taxes of up to $60 million generated from this program are not included in the outlook for 2014.

Fresenius SE & Co. KGaA holds approximately 30.5% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA
Represented by Fresenius Medical Care Management AG
Represented by its Management Board
Bad Homburg v.d.H., February 24, 2014

]]>
news-161 Tue, 26 Feb 2013 10:46:00 +0100 Fresenius Medical Care Reports Full Year 2012 Results and provides Outlook for 2013 /en/media/news/details/detail/News/fresenius-medical-care-reports-full-year-2012-results-and-provides-outlook-for-2013/ Fresenius Medical Care has achieved its targets for the financial year 2012.

Net revenue of Fresenius Medical Care AG & Co. KGaA for the full year 2012 was $13,800 million, up by 10% from the full year 2011.

Operating income (EBIT) for the full year 2012 increased by 7% to $2,219 million compared to $2,075 million for the full year 2011. Excluding one-time costs the operating income for the full year 2012 increased by 12% to $2,329 million.

For the full year 2012, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA was $1,187 million, up 11% from the full year 2011. Excluding a positive non-taxable investment gain in the amount of $140 million and one-time costs in the amount of $71 million, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA was $1,118 million, an increase of 4% compared to 2011.

For the 16th consecutive year shareholders can expect to receive an increased annual dividend. At the Annual General Meeting to be held on May 16, 2013, shareholders will be asked to approve a dividend per ordinary share of €0.75, an increase of 9% (2011: €0.69).

For the full year 2013, Fresenius Medical Care expects revenue to grow to more than $14.6 billion. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.1 and $1.2 billion. Based on the net income for 2012 excluding the investment gain, the expected earnings growth in 2013 is between 5% and 15%.

Fresenius SE & Co. KGaA (WKN 578560) holds 30.77% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA
Represented by Fresenius Medical Care Management AG
Represented by its Management Board
Bad Homburg v.d.H., February 26, 2013

***

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.2 million individuals worldwide. Through its network of 3,160 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 257,916 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release

***

]]>
news-165 Tue, 21 Feb 2012 16:16:00 +0100 Fresenius Medical Care Reports Record Full Year 2011 Results and provides Outlook for 2012 /en/media/news/details/detail/News/fresenius-medical-care-reports-record-full-year-2011-results-and-provides-outlook-for-2012/ Net revenue of Fresenius Medical Care AG & Co. KGaA for the full year 2011 was $12,795 million, up by 6% from the full year 2010.

Operating income (EBIT) for the full year 2011 was $2,075 million, up by 8% from the full year 2010. For the full year 2011, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA was $1,071 million, up 9% from the full year 2010.

For the 15th consecutive year shareholders can expect to receive an increased annual dividend. At the Annual General Meeting to be held on May 10, 2012, shareholders will be asked to approve a dividend per ordinary share of €0.69, an increase of 6% (2010: €0.65).

For the full year 2012, Fresenius Medical Care expects revenue to grow to around $14 billion. This revenue guidance takes into account the first time adoption in 2012 of an U.S. - GAAP accounting change in the presentation of U.S. dialysis service revenue which will be shown net of the provision for bad debt. Based on the comparable revenue for 2011 of $12,571 million, the revenue guidance represents an increase of 11% and between 13% and 15% based on constant currency.

Net income is expected to grow to around $1.3 billion and net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to grow to around $1.14 billion with operating margins forecast to increase by approximately 70 basis points to 16.9%.

For 2012, Fresenius Medical Care expects to spend around $700 million on capital expenditure and approximately $1.8 billion on acquisitions.

Fresenius SE & Co. KGaA (WKN 578560) holds approximately 30.9% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA,
Represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., February 21, 2012

   
***

About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 2,898 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 233,156 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

***

]]>
news-56 Tue, 20 Dec 2011 00:00:00 +0100 Fresenius Medical Care Confirms Outlook on Targeted Earnings After Tax and revises its Outlook for Full Year 2011 Revenue /en/media/news/details/detail/News/fresenius-medical-care-confirms-outlook-on-targeted-earnings-after-tax-and-revises-its-outlook-for-full-year-2011-revenue/ Fresenius Medical Care AG & Co. KGaA (“the Company”), the world’s largest provider of dialysis products and services, today announced revised outlook for revenue to be approximately 1.0% to 2.0% below the US-Dollar 13 billion benchmark. The impact on the revenue is predominately due to significant weakening of the Euro and other currencies against the US-Dollar in the fourth quarter of 2011. Nevertheless, the Company continues to confirm its earnings after tax target in US-Dollar although expectations are that the net income attributable to the Company will be at the low end of the target range of US-Dollar 1,070-1,090 m, principally due to the additional one-time costs incurred in 2011 related to acquisitions.

Ben Lipps, Chief Executive Officer and Chairman of the Management Board of Fresenius Medical Care: “The company is having another excellent year in 2011, meeting also the challenges of the reimbursement reform in the United States, growing our business substantially in all regions and managing the integration of a number of significant acquisitions.”

***

About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,874 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 228,239 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.      

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


***

]]>
news-57 Tue, 02 Aug 2011 00:10:00 +0200 Fresenius Medical Care plans to acquire 100% of U.S. based Liberty Dialysis Holdings, Inc /en/media/news/details/detail/News/fresenius-medical-care-plans-to-acquire-100-of-us-based-liberty-dialysis-holdings-inc/ Fresenius Medical Care has executed a merger agreement with Liberty Dialysis Holdings, Inc., the holding company for Liberty Dialysis and Renal Advantage. The investment, including assumed debt, will be approximately $1.7bn. In addition, Fresenius Medical Care previously invested approximately $ 300 million in Renal Advantage. The merger is subject to clearance under the Hart–Scott–Rodino Antitrust Improvements Act and is expected to close in early 2012. Liberty Dialysis Holdings, Inc. has annual sales of approximately $ 1bn and operates approximately 260 dialysis clinics. The transaction will be financed from cash flow from operations and debt and is expected to be accretive to earnings in the first year after closing of the transaction.

Fresenius Medical Care AG & Co. KGaA,
represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., August 2, 2011

***

About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,838 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 225,909 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. 

***

]]>
news-58 Wed, 04 May 2011 00:00:00 +0200 Adhoc: Fresenius Medical Care Reports First Quarter 2011 Results and Raises Outlook for 2011 /en/media/news/details/detail/News/adhoc-fresenius-medical-care-reports-first-quarter-2011-results-and-raises-outlook-for-2011/ Net revenue of Fresenius Medical Care AG & Co. KGaA increased by 5% to $3,036 million (+5% at constant currency) in the first quarter of 2011. Operating income (EBIT) increased by 5% to $445 million. Net income for the first quarter of 2011 was $221 million, an increase of 5%.

Based on the strong financial results in the first quarter of 2011 and the elimination of the so-called “transition adjustment” imposed on dialysis facilities as part of the new Medicare end-stage renal disease prospective payment system in the United States, the company raises its outlook for the full year 2011.

The company now expects to achieve revenue of more than $13 billion. Previously, the company expected revenue to grow to between $12.8 billion and $13.0 billion.

Net income attributable to Fresenius Medical Care AG & Co. KGaA is now expected to be between $1.070 billion to $1.090 billion in 2011. Previously, the company expected net income to be between $1.035 billion and $1.055 billion.

For 2011, the company still expects to spend around 5% of revenue on capital expenditures and approximately $1.2 billion on acquisitions. The debt/EBITDA ratio is expected to be below or equal to 2.8 by the end of 2011, likewise unchanged from the previous guidance.


Fresenius Medical Care AG & Co. KGaA,
represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., May 4, 2011

***

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,769 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 216,942 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

 
***

]]>
news-59 Wed, 23 Feb 2011 00:00:00 +0100 Adhoc: Fresenius Medical Care Reports Full Year 2010 Results /en/media/news/details/detail/News/adhoc-fresenius-medical-care-reports-full-year-2010-results/ Net revenue of Fresenius Medical Care AG & Co. KGaA for the full year 2010 was $12,053 million, up 7% from the full year 2009.

Operating income (EBIT) increased by 10% to $1,924 million.

For the full year 2010, net income attributable to Fresenius Medical Care AG & Co. KGaA was $979 million, up 10% from 2009.

For the 14th consecutive year, shareholders can expect to receive an increased annual dividend. At the Annual General Meeting to be held on May 12, 2010, shareholders will be asked to approve a dividend per ordinary share of €0.65, an increase of 7% (2009: €0.61).

For the full year 2011, Fresenius Medical Care expects revenue to grow to between US$ 12.8 billion and US$ 13.0 billion, corresponding to a growth rate of 6% to 8%. Net income attributable to Fresenius Medical Care AG & Co. KGaA is expected to be between US$1.035 billion and US$1.055 billion, with operating margins forecast to increase by approximately 20 basis points. The net income guidance does not consider a reduction of the "transition adjuster" for US clinics in 2011.

For 2011, Fresenius Medical Care expects to spend around 5 % of revenue on capital expenditure and approximately $ 1.2 billion on acquisitions.


Fresenius SE (WKN 578560) holds approximately 35% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA,
Represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., February 23, 2011

***
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,757 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 214,648 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
***

]]>
news-166 Wed, 01 Dec 2010 16:18:00 +0100 Fresenius Medical Care and Galenica form renal pharmaceutical company /en/media/news/details/detail/News/fresenius-medical-care-and-galenica-form-renal-pharmaceutical-company/ Fresenius Medical Care AG & Co. KGaA today announced the formation of a new renal pharmaceutical company named Vifor-Fresenius Medical Care Renal Pharma Ltd. and designed to develop and distribute on a world wide basis products to treat iron deficiency anaemia and bone mineral metabolism for pre-dialysis and dialysis patients. The products of the new company will include Venofer® and Ferinject® (Injectafer®, the brand name for Ferinject® in the USA) within the field of dialysis and pre-dialysis (CKD stage III – V) as well as PA21, a novel iron-based phosphate binder. The newly formed company, with headquarters in Switzerland, extends existing agreements with Galenica. The existing customer and distribution agreements will stay in place.This investment allows Fresenius Medical Care to take the next major implementation step in its renal pharmaceutical strategy. Fresenius Medical Care will hold a 45% share in the new company. The transaction is subject to final anti-trust approval in certain regions.

Fresenius SE (WKN 578560, 578563) holds approximately 36% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA,
Represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., December 01, 2010

]]>
news-43 Wed, 24 Feb 2010 00:00:00 +0100 Adhoc: Fresenius Medical Care Reports Full Year 2009 Results /en/media/news/details/detail/News/adhoc-fresenius-medical-care-reports-full-year-2009-results/ Net revenue of Fresenius Medical Care AG & Co. KGaA was $11,247 million in 2009, up 6% compared to 2008. At constant currency, net revenue rose by 9%.

Operating income (EBIT) increased by 5% to $1,756 million.

For the full year 2009, net income attributable to Fresenius Medical Care AG & Co. KGaA was $891 million, up 9% from 2008.

For the thirteenth consecutive year, shareholders can expect to receive an increased annual dividend. At the Annual General Meeting to be held on May 11, 2010, shareholders will be asked to approve a dividend per ordinary share of €0.61, an increase of 5% (2008: €0.58).

For the full year 2010, the Company expects to achieve revenue of more than $12 billion. Net income attributable to Fresenius Medical Care AG & Co. KGaA is expected to be between $950 million and $980 million in 2010.

The Company expects to spend $550 to $650 million on capital expenditures and up to $400 million on acquisitions.

Fresenius SE (WKN 578560, 578563) holds approximately 36% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA,
Represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., February 24, 2010 

]]>